Finance
Stada in talks with two private equity groups over sale, Welt reports
Published by Global Banking & Finance Review®
Posted on June 3, 2025
1 min readLast updated: January 23, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on June 3, 2025
1 min readLast updated: January 23, 2026
Stada is negotiating with private equity firms for a sale, with an IPO as a backup plan. Earnings rose 5% in Q1, driven by specialty pharmaceuticals.
BERLIN (Reuters) -German pharmaceutical firm Stada is in talks with two private equity investors about a sale, Germany's Welt newspaper reported on Tuesday.
Its owners Bain Capital and Cinven could seek an initial public offering in October if talks on a sale do not come to fruition, the report cited an unnamed source as saying.
A Stada spokesperson told Reuters the company was deliberating with its owners all options regarding the future ownership of the maker of generic drugs and consumer health products, including an IPO and a sale.
Reuters in March cited people familiar with the matter as saying that Stada postponed a planned IPO in Frankfurt because of market volatility.
Earlier on Tuesday, Stada said first-quarter operating earnings before special items rose a currency-adjusted 5% to 245 million euros ($279 million), driven by higher sales of specialty pharmaceuticals.
($1 = 0.8783 euros)
(Writing by Friederike HeineEditing by Ludwig Burger)
Stada is in talks with two private equity investors about a potential sale.
If the sale talks do not come to fruition, Stada's owners, Bain Capital and Cinven, could seek an initial public offering in October.
Stada reported that first-quarter operating earnings before special items rose a currency-adjusted 5% to 245 million euros, driven by higher sales of specialty pharmaceuticals.
Explore more articles in the Finance category
